WWH (Washington DC)

In December 2013, the Division of AIDS of the National Institute of Allergy and Infectious Diseases selected Whitman-Walker Health as the only new domestic Clinical Research Site in the most recent competition for funding. WWH was thrilled to join the AIDS Clinical Trials Group and to provide its patients access to the cutting-edge, scientific work in the ACTG. Since becoming an ACTG site, WWH is proud to have enrolled nearly 150 participants into 15 distinct ACTG trials and continues to thrive and grow as a site. WWH has a long history of participating in advanced clinical research, starting in 1987 when some of the early trials on AZT for HIV treatment were conducted here. Since then, the health center’s investigators and staff have conducted over 350 studies that have included over 4,000 patients; one cohort study currently alone has over 2,500 enrolled participants. 

WWH’s research studies look at new and better ways to treat or prevent diseases in the community, like HIV, hepatitis B and C, and high cholesterol. WWH’s portfolio includes clinical trials that test how well new medications work and how safe the medications are for patients; as well as behavioral studies that look at such topics as disease prevention and medical adherence. WWH has expanded into research related to HIV cure and vaccines, and intersectionality effects on biomarkers. WWH also helped set up the first transgender women’s longitudinal cohort study in the nation.

WWH has worked closely with the National Institutes of Health and the Johns Hopkins University Bloomberg School of Public Health on the Multicenter AIDS Cohort Study and multiple HIV/STI prevention projects. The health center has also collaborated with industry sponsors to evaluate all of the current therapies used to treated HIV and viral hepatitis. The effectiveness and tolerability of these medications have changed dramatically over the past 20 years. WWH and its patients have been at the forefront of contributing to research that has led to all of the currently approved single tablet regimens for HIV and the direct acting agents for hepatitis C treatment. Becoming a part of the ACTG has offered WWH the opportunity to conduct additional areas of research, including cure research and studies on more novel immunotherapies for HIV.

The WWH CRS operates from two sites in Northwest Washington, DC. Most patient visits are conducted at WWH’s site at 1525 14th Street NW, a state of the art facility that opened in May 2015. The WWH CRS Coordinator and ACTG staff offices and industry-sponsored studies are located there, as well as WWH’s main medical, dental, and behavioral health services and pharmacy. WWH’s second site, located at 1145 19th Street NW, houses our large HIV PrEP study, our SHARE/MACS Cohort Study and their staff; as well as our Data Manager offices and our blood apheresis facility, for use in ACTG and other clinical trials.

Translating research into clinical practice and bridging community efforts and scientific initiatives to combat HIV are at the center of WWH’s mission and values. The health center is thrilled to collaborate with JHU and BJMC as part of the ACTG and looks forward to making significant advancements in HIV and hepatitis research.

Clinical Trials

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

The study is designed to characterize the pharmacokinetics of DLM using a model-based approach, and to evaluate safety and...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More